NasdaqCM:VCNX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs.


Snowflake Analysis

Limited growth with worrying balance sheet.

Share Price & News

How has Vaccinex's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VCNX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.1%

VCNX

-0.9%

US Biotechs

2.5%

US Market


1 Year Return

-44.5%

VCNX

24.5%

US Biotechs

8.4%

US Market

Return vs Industry: VCNX underperformed the US Biotechs industry which returned 24.5% over the past year.

Return vs Market: VCNX underperformed the US Market which returned 8.4% over the past year.


Shareholder returns

VCNXIndustryMarket
7 Day-4.1%-0.9%2.5%
30 Day-11.1%3.2%5.1%
90 Day-29.6%13.6%2.0%
1 Year-44.5%-44.5%25.7%24.5%10.9%8.4%
3 Yearn/a32.2%27.8%30.5%21.9%
5 Yearn/a-3.4%-9.2%56.9%39.2%

Price Volatility Vs. Market

How volatile is Vaccinex's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Vaccinex undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Vaccinex is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Vaccinex has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Vaccinex forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

63.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VCNX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VCNX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VCNX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VCNX's revenue (77.7% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: VCNX's revenue (77.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VCNX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Vaccinex performed over the past 5 years?

-11.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VCNX is currently unprofitable.

Growing Profit Margin: VCNX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VCNX is unprofitable, and losses have increased over the past 5 years at a rate of -11.2% per year.

Accelerating Growth: Unable to compare VCNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VCNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: VCNX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Vaccinex's financial position?


Financial Position Analysis

Short Term Liabilities: VCNX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: VCNX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: VCNX is debt free.

Reducing Debt: VCNX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VCNX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: VCNX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 16% each year


Next Steps

Dividend

What is Vaccinex's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VCNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VCNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VCNX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VCNX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VCNX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

11.4yrs

Average management tenure


CEO

Maurice Zauderer (73yo)

19.08yrs

Tenure

US$398,872

Compensation

Dr. Maurice Zauderer, Ph.D. Co-Founded Vaccinex, Inc. in April 2001 and also serves as its President and Chief Executive Officer since April 2001. Dr. Zauderer serves as Director of Vaccinex Inc. since Apr ...


CEO Compensation Analysis

Compensation vs Market: Maurice's total compensation ($USD398.87K) is below average for companies of similar size in the US market ($USD587.77K).

Compensation vs Earnings: Maurice's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Maurice Zauderer
Co-Founder19.08yrsUS$398.87k3.62% $2.3m
Raymond Watkins
Senior VP & COO14.33yrsUS$263.24k0.047% $29.6k
Ernest Smith
Senior VP of Research & Chief Scientific Officer11.42yrsUS$263.24k0.048% $30.2k
Deepak Sahasrabudhe
Co-Founderno datano datano data
Scott Royer
Chief Financial Officer2.25yrsno data0.024% $15.1k
John Leonard
Senior Vice President of Development11.33yrsno data0.0061% $3.8k

11.4yrs

Average Tenure

60yo

Average Age

Experienced Management: VCNX's management team is seasoned and experienced (11.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Maurice Zauderer
Co-Founder19.08yrsUS$398.87k3.62% $2.3m
Deepak Sahasrabudhe
Co-Founderno datano datano data
Bala Manian
Independent Director15.42yrsUS$75.00kno data
Gerald Van Strydonck
Independent Director17.17yrsUS$90.00kno data
J. Goater
Independent Director7yrsUS$82.50k0.0018% $1.1k
Max Vasquez
Member of Scientific & Clinical Advisory Boardno datano datano data
Mark Tullman
Scientific and Clinical Advisorno datano datano data
Albert Friedberg
Chairman of the Board19.08yrsno data2.64% $1.7m
Barbara Yanni
Independent Director5.25yrsUS$85.00kno data
Jacob Frieberg
Independent Lead Directorno dataUS$75.00k0.32% $199.3k

16.3yrs

Average Tenure

72yo

Average Age

Experienced Board: VCNX's board of directors are seasoned and experienced ( 16.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 45%.


Top Shareholders

Company Information

Vaccinex, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vaccinex, Inc.
  • Ticker: VCNX
  • Exchange: NasdaqCM
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$62.747m
  • Shares outstanding: 16.64m
  • Website: https://www.vaccinex.com

Number of Employees


Location

  • Vaccinex, Inc.
  • 1895 Mount Hope Avenue
  • Rochester
  • New York
  • 14620
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VCNXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDAug 2018

Biography

Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), Huntington’s disease, osteosarcoma, melanoma, and Alzheimer’s disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; and VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/28 04:13
End of Day Share Price2020/05/27 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.